Manjurul
- CureVac (NASDAQ:CVAC) is trading 5.6% higher premarket after it announced positive data from its Phase 1 trial of its vaccine candidate, CV0501, to treat COVID-19 in collaboration with GSK.
- The data showed that monovalent modified mRNA construct CV0501 boosted antibody titers against BA.1 and ancestral variants in adults aged ≥65.
- The company recruited dose groups of 12, 25 and 50µg, consisting of 10 subjects per dose. The vaccine showed relevant titers of neutralizing antibodies beginning at the lowest tested dose, the company said.
- A phase 1 trial testing vaccine candidate Flu-SV-mRNA elicited antibodies about 2.3 times those of licensed vaccine comparator in adults aged 60-80.
- The company reaffirmed its plan to advance modified mRNA COVID-19 and flu candidates to the next stages of clinical development in collaboration with GSK in 2023.
- A Phase 2 clinical study, expected to start later in 2023, will assess monovalent and/or bivalent vaccine candidates.